Sonus Pharmaceuticals to Present at the Roth Capital Partners 17th Annual Growth Stock Conference.BOTHELL, Wash. -- Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS SNUS Swedish National Union of Students ) today announced that Michael A. Martino, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will be presenting on Wednesday, February 23, 2005, 12:30 P.M. Pacific Time, at the Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, 17th Annual Growth Stock Conference. The Company's presentation will be broadcast live and archived on the Sonus web site at http://www.sonuspharma.com/events.html. Mr. Martino will provide a company overview and review progress of Sonus' strategic initiatives, including the development of its lead product candidate, TOCOSOL(R) Paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); , a new formulation of the widely prescribed anti-cancer drug paclitaxel. TOCOSOL Paclitaxel has been designed to overcome the limitations associated with Taxol(R) and generic paclitaxel-based chemotherapy, including long infusion times, undesirable or treatment-limiting side effects Side effects Effects of a proposed project on other parts of the firm. as well as time consuming and expensive preparation prior to administration. Sonus is currently in discussions with the U.S. Food and Drug Administration to finalize the pivotal Phase 3 protocol for TOCOSOL Paclitaxel, which the Company believes will be initiated in 2005. About Sonus Pharmaceuticals, Inc. Headquartered near Seattle, Sonus Pharmaceuticals, Inc. is focused on the development of novel drugs that may offer improved administration, safety, tolerability and effectiveness for the treatment of cancer and related therapies. In addition to executing its plans for TOCOSOL Paclitaxel, the Company remains focused on driving product and corporate development activities towards building and expanding its pipeline of oncology and related product candidates. For additional information, including past press releases, please visit the Sonus web site at www.sonuspharma.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of drug delivery products and potential applications for these products. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. filed on March 12, 2004 and Quarterly Report on Form 10-Q Form 10-Q See 10-Q. filed November 15, 2004, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies; risks that clinical studies with TOCOSOL Paclitaxel will not be successful; risks that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. may not approve the Company's proposed New Drug Application; and risks of successful development of additional drug delivery products. Sonus undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof. Taxol(R) is a registered trademark of Bristol-Myers Squibb Company. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion